Trial Profile
A multicentre phase II trial of extended treatment with rituximab to assess complete remission rate in patients with B-cell post-transplant lymphoproliferative diease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Vincristine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Lymphoproliferative disorders; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 01 Apr 2021 Results assessing long-term survival of patients diagnosed of post-transplant lymphoproliferative disease after solid organ transplant and treated with rituximab monotherapy in first line therapy, published in the Annals of Hematology.
- 29 Jun 2016 New trial record